Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,774 public trials 698 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035

Conditions
Blood Protein Disorders, Burkitt Lymphoma, CLL, +47 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Los Angeles, California, United States
  • Research Site Denver, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
View all 19 locations
View Trial Details
Completed

Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma

NCT01208896

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University Hospital Angers Angers, France
  • Service Hématologie, Hôpital Minjoz Besançon, France
  • Service Hématologie, Hôpital Augustin Morvan Brest, France
  • University Hospital, Caen Caen, France
View all 26 locations
View Trial Details
Completed

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

NCT03274492

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Southern Cancer Center Daphne, Alabama, United States
  • City of Hope Duarte, California, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
View all 209 locations
View Trial Details
Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Unviersity of Wisconsin Madison, Wisconsin, United States
View Trial Details
Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +58 more
Locations
  • University of Colorado Denver, Colorado, United States
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

NCT03902184

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California, Los Angeles (UCLA) - Medical Center Los Angeles, California, United States
  • Irvine Medical Center Orange, California, United States
  • Stanford University Stanford, California, United States
View all 53 locations
View Trial Details

Related conditions